Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

eIF2B activator prevents neurological defects caused by a chronic integrated stress response.

Wong YL, LeBon L, Basso AM, Kohlhaas KL, Nikkel AL, Robb HM, Donnelly-Roberts DL, Prakash J, Swensen AM, Rubinstein ND, Krishnan S, McAllister FE, Haste NV, O'Brien JJ, Roy M, Ireland A, Frost JM, Shi L, Riedmaier S, Martin K, Dart MJ, Sidrauski C.

Elife. 2019 Jan 9;8. pii: e42940. doi: 10.7554/eLife.42940.

2.

Short-term oral gavage administration of adenine induces a model of fibrotic kidney disease in rats.

Zhu CZ, Doyle KJ, Nikkel AL, Olsen L, Namovic MT, Salte K, Widomski D, Su Z, Donnelly-Roberts DL, Gopalakrishnan MM, McGaraughty S.

J Pharmacol Toxicol Methods. 2018 Nov - Dec;94(Pt 1):34-43. doi: 10.1016/j.vascn.2018.04.003. Epub 2018 Apr 22.

PMID:
29684554
3.

Characterization and comparison of rat monosodium iodoacetate and medial meniscal tear models of osteoarthritic pain.

Brederson JD, Chu KL, Xu J, Nikkel AL, Markosyan S, Jarvis MF, Edelmayer R, Bitner RS, McGaraughty S.

J Orthop Res. 2018 Feb 11. doi: 10.1002/jor.23869. [Epub ahead of print]

4.

Losartan improves renal function and pathology in obese ZSF-1 rats.

Su Z, Widomski D, Nikkel A, Leys L, Namovic M, Donnelly-Roberts D, Gopalakrishnan M, McGaraughty S.

J Basic Clin Physiol Pharmacol. 2018 Jun 27;29(3):281-290. doi: 10.1515/jbcpp-2017-0157.

PMID:
29397387
5.

Targeting Anti-TGF-β Therapy to Fibrotic Kidneys with a Dual Specificity Antibody Approach.

McGaraughty S, Davis-Taber RA, Zhu CZ, Cole TB, Nikkel AL, Chhaya M, Doyle KJ, Olson LM, Preston GM, Grinnell CM, Salte KM, Giamis AM, Luo Y, Sun V, Goodearl AD, Gopalakrishnan M, Lacy SE.

J Am Soc Nephrol. 2017 Dec;28(12):3616-3626. doi: 10.1681/ASN.2017010013. Epub 2017 Aug 21.

6.

Longitudinal Changes in Measured Glomerular Filtration Rate, Renal Fibrosis and Biomarkers in a Rat Model of Type 2 Diabetic Nephropathy.

Su Z, Widomski D, Ma J, Namovic M, Nikkel A, Leys L, Olson L, Salte K, Donnelly-Roberts D, Esbenshade T, McGaraughty S.

Am J Nephrol. 2016;44(5):339-353. Epub 2016 Oct 14.

7.

A-306989, an inhibitor of adenosine kinase, is renoprotective in rodent models of podocyte, basement membrane, and obstructive injury.

Zhu CZ, Gopalakrishnan S, Doyle K, Nikkel AL, Olson L, Abraham VC, Leys L, Widomski D, Salte K, Putman B, Pratt S, Ma J, Su Z, Gopalakrishnan M, Lee CH, McGaraughty SP.

Eur J Pharmacol. 2016 Oct 5;788:1-11. doi: 10.1016/j.ejphar.2016.06.012. Epub 2016 Jun 8.

PMID:
27288879
8.

The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo.

Nikkel AL, Martino B, Markosyan S, Brederson JD, Medeiros R, Moeller A, Bitner RS.

Neuropharmacology. 2012 Sep;63(4):606-12. doi: 10.1016/j.neuropharm.2012.05.011. Epub 2012 May 18.

PMID:
22613839
9.

In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer's disease.

Bitner RS, Markosyan S, Nikkel AL, Brioni JD.

Neuropharmacology. 2011 Feb-Mar;60(2-3):460-6. doi: 10.1016/j.neuropharm.2010.10.026. Epub 2010 Oct 31.

PMID:
21044639
10.

In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.

Bitner RS, Bunnelle WH, Decker MW, Drescher KU, Kohlhaas KL, Markosyan S, Marsh KC, Nikkel AL, Browman K, Radek R, Anderson DJ, Buccafusco J, Gopalakrishnan M.

J Pharmacol Exp Ther. 2010 Sep 1;334(3):875-86. doi: 10.1124/jpet.110.167213. Epub 2010 May 26.

PMID:
20504913
11.

Selective alpha7 nicotinic acetylcholine receptor activation regulates glycogen synthase kinase3beta and decreases tau phosphorylation in vivo.

Bitner RS, Nikkel AL, Markosyan S, Otte S, Puttfarcken P, Gopalakrishnan M.

Brain Res. 2009 Apr 10;1265:65-74. doi: 10.1016/j.brainres.2009.01.069. Epub 2009 Feb 20.

PMID:
19230830
12.

Localization of histamine H4 receptors in the central nervous system of human and rat.

Strakhova MI, Nikkel AL, Manelli AM, Hsieh GC, Esbenshade TA, Brioni JD, Bitner RS.

Brain Res. 2009 Jan 23;1250:41-8. doi: 10.1016/j.brainres.2008.11.018. Epub 2008 Nov 19.

PMID:
19046950
13.

Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties.

Tietje KR, Anderson DJ, Bitner RS, Blomme EA, Brackemeyer PJ, Briggs CA, Browman KE, Bury D, Curzon P, Drescher KU, Frost JM, Fryer RM, Fox GB, Gronlien JH, Håkerud M, Gubbins EJ, Halm S, Harris R, Helfrich RJ, Kohlhaas KL, Law D, Malysz J, Marsh KC, Martin RL, Meyer MD, Molesky AL, Nikkel AL, Otte S, Pan L, Puttfarcken PS, Radek RJ, Robb HM, Spies E, Thorin-Hagene K, Waring JF, Ween H, Xu H, Gopalakrishnan M, Bunnelle WH.

CNS Neurosci Ther. 2008 Spring;14(1):65-82. doi: 10.1111/j.1527-3458.2008.00037.x. Review.

14.

Analysis of gene expression profiles in rat hippocampus following treatment with nicotine and an alpha7 nAChR selective agonist.

Waring JF, Abel S, Li J, Bitner RS, Nikkel AL, Blomme EA, Anderson DJ, Gopalakrishnan M.

Neurosci Res. 2008 Mar;60(3):266-74. doi: 10.1016/j.neures.2007.11.008. Epub 2007 Nov 22.

PMID:
18164502
15.

Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways.

Bitner RS, Bunnelle WH, Anderson DJ, Briggs CA, Buccafusco J, Curzon P, Decker MW, Frost JM, Gronlien JH, Gubbins E, Li J, Malysz J, Markosyan S, Marsh K, Meyer MD, Nikkel AL, Radek RJ, Robb HM, Timmermann D, Sullivan JP, Gopalakrishnan M.

J Neurosci. 2007 Sep 26;27(39):10578-87.

16.

Antisense knockdown of the rat alpha7 nicotinic acetylcholine receptor produces spatial memory impairment.

Curzon P, Anderson DJ, Nikkel AL, Fox GB, Gopalakrishnan M, Decker MW, Bitner RS.

Neurosci Lett. 2006 Dec 13;410(1):15-9. Epub 2006 Oct 20.

PMID:
17055644
17.

Distinctions and contradistinctions between antiobesity histamine H(3) receptor (H (3)R) antagonists compared to cognition-enhancing H (3) receptor antagonists.

Hancock AA, Bitner RS, Krueger KM, Otte S, Nikkel AL, Fey TA, Bush EN, Dickinson RW, Shapiro R, Knourek-Segel V, Droz BA, Brune ME, Jacobson PB, Cowart MD, Esbenshade TA.

Inflamm Res. 2006 Apr;55 Suppl 1:S42-4. No abstract available.

PMID:
16547814
18.

Dissociation between post-surgical pain behaviors and spinal Fos-like immunoreactivity in the rat.

Zhu CZ, Nikkel AL, Martino B, Bitner RS, Decker MW, Honore P.

Eur J Pharmacol. 2006 Feb 15;531(1-3):108-17. Epub 2006 Jan 24.

PMID:
16438960
19.

Dopamine D4 receptor signaling in the rat paraventricular hypothalamic nucleus: Evidence of natural coupling involving immediate early gene induction and mitogen activated protein kinase phosphorylation.

Bitner RS, Nikkel AL, Otte S, Martino B, Barlow EH, Bhatia P, Stewart AO, Brioni JD, Decker MW, Moreland RB.

Neuropharmacology. 2006 Apr;50(5):521-31. Epub 2005 Dec 1.

PMID:
16324724
20.

Preclinical profiling and safety studies of ABT-769: a compound with potential for broad-spectrum antiepileptic activity.

Giardina WJ, Dart MJ, Harris RR, Bitner RS, Radek RJ, Fox GB, Chemburkar SR, Marsh KC, Waring JF, Hui JY, Chen J, Curzon P, Grayson GK, Komater VA, Ku Y, Lockwood M, Miner HM, Nikkel AL, Pan JB, Pu YM, Wang L, Bennani Y, Durmuller N, Jolly R, Roux S, Sullivan JP, Decker MW.

Epilepsia. 2005 Sep;46(9):1349-61.

21.

In vitro and in vivo effects of an alpha3 neuronal nicotinic acetylcholine receptor antisense oligonucleotide.

Adams MR, Nikkel AL, Donnelly-Roberts DL, Watt AT, Johnston JF, Cowsert LM, Butler M, Kroeger PE, Frost L, Curzon P, Decker MW, Bitner RS.

Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):67-79.

PMID:
15469883
22.

Capsaicin infused into the PAG affects rat tail flick responses to noxious heat and alters neuronal firing in the RVM.

McGaraughty S, Chu KL, Bitner RS, Martino B, El Kouhen R, Han P, Nikkel AL, Burgard EC, Faltynek CR, Jarvis MF.

J Neurophysiol. 2003 Oct;90(4):2702-10. Epub 2003 Jun 18.

23.

Differential in vivo effects of H3 receptor ligands in a new mouse dipsogenia model.

Fox GB, Pan JB, Esbenshade TA, Bitner RS, Nikkel AL, Miller T, Kang CH, Bennani YL, Black LA, Faghih R, Hancock AA, Decker MW.

Pharmacol Biochem Behav. 2002 Jun;72(3):741-50.

PMID:
12175472
24.
25.

Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat.

Bitner RS, Nikkel AL, Curzon P, Donnelly-Roberts DL, Puttfarcken PS, Namovic M, Jacobs IC, Meyer MD, Decker MW.

Brain Res. 2000 Jul 14;871(1):66-74.

PMID:
10882784
26.

Differences between the antinociceptive effects of the cholinergic channel activators A-85380 and (+/-)-epibatidine in rats.

Curzon P, Nikkel AL, Bannon AW, Arneric SP, Decker MW.

J Pharmacol Exp Ther. 1998 Dec;287(3):847-53.

PMID:
9864263
27.

The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594.

Decker MW, Curzon P, Holladay MW, Nikkel AL, Bitner RS, Bannon AW, Donnelly-Roberts DL, Puttfarcken PS, Kuntzweiler TA, Briggs CA, Williams M, Arneric SP.

J Physiol Paris. 1998 Jun-Aug;92(3-4):221-4. Review.

PMID:
9789812
29.
30.

Hyperactivity and behavioral seizures in rodents following treatment with the dopamine D1 receptor agonists A-86929 and ABT-431.

Shiosaki K, Asin KE, Britton DR, Giardina WJ, Bednarz L, Mahan L, Mikusa J, Nikkel A, Wismer C.

Eur J Pharmacol. 1996 Dec 19;317(2-3):183-90.

PMID:
8997599
31.
32.

Amphetamine induces Fos-like immunoreactivity in the striatum of primates.

Asin KE, Wirtshafter D, Nikkel A.

Brain Res. 1996 May 6;719(1-2):138-42.

PMID:
8782873
33.

ABT-431: the diacetyl prodrug of A-86929, a potent and selective dopamine D1 receptor agonist: in vitro characterization and effects in animal models of Parkinson's disease.

Shiosaki K, Jenner P, Asin KE, Britton DR, Lin CW, Michaelides M, Smith L, Bianchi B, Didomenico S, Hodges L, Hong Y, Mahan L, Mikusa J, Miller T, Nikkel A, Stashko M, Witte D, Williams M.

J Pharmacol Exp Ther. 1996 Jan;276(1):150-60.

PMID:
8558425
34.

Rotation and striatal c-fos expression after repeated, daily treatment with selective dopamine receptor agonists and levodopa.

Asin KE, Bednarz L, Nikkel A, Perner R.

J Pharmacol Exp Ther. 1995 Jun;273(3):1483-90.

PMID:
7791123
35.

CCK-A-selective tetrapeptides containing lys(N epsilon)-amide residues: favorable in vivo and in vitro effects of N-methylation at the aspartyl residue.

Bennett MJ, Nikkel AL, Bianchi BR, Miller TR, Bednarz L, Witte DG, Stashko M, Wang SS, Gore PA, Asin KE, et al.

J Med Chem. 1994 May 27;37(11):1569-71.

PMID:
8201591
36.

Tetrapeptide CCK-A agonists: effect of backbone N-methylations on in vitro and in vivo CCK activity.

Holladay MW, Kopecka H, Miller TR, Bednarz L, Nikkel AL, Bianchi BR, Witte DG, Shiosaki K, Lin CW, Asin KE, et al.

J Med Chem. 1994 Mar 4;37(5):630-5.

PMID:
8126703
37.

Repeated D1 receptor agonist treatment blocks cocaine-induced locomotor activity and c-fos expression.

Asin KE, Nikkel AL, Wirtshafter D.

Brain Res. 1994 Feb 21;637(1-2):342-4.

PMID:
7910104
38.

A-71623, a selective CCK-A receptor agonist, suppresses food intake in the mouse, dog, and monkey.

Asin KE, Bednarz L, Nikkel AL, Gore PA Jr, Nadzan AM.

Pharmacol Biochem Behav. 1992 Aug;42(4):699-704.

PMID:
1513850
39.

Synthesis and biological activity of CCK heptapeptide analogues. Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro, and appetite suppression in vivo.

Holladay MW, Bennett MJ, Tufano MD, Lin CW, Asin KE, Witte DG, Miller TR, Bianchi BR, Nikkel AL, Bednarz L, et al.

J Med Chem. 1992 Aug 7;35(16):2919-28.

PMID:
1501220
40.

Behavioral effects of A71623, a highly selective CCK-A agonist tetrapeptide.

Asin KE, Bednarz L, Nikkel AL, Gore PA Jr, Montana WE, Cullen MJ, Shiosaki K, Craig R, Nadzan AM.

Am J Physiol. 1992 Jul;263(1 Pt 2):R125-35.

PMID:
1636779

Supplemental Content

Loading ...
Support Center